彭丁,王韶屏,柳景华,白雪莲

• 1:首都医科大学附属北京安贞医院心内科北京市心肺血管疾病研究所
• 2:煤炭总医院超声诊断科

摘要(Abstract)：

目的探讨冠心病心力衰竭患者血运重建术后心脏性猝死(sudden cardiac death,SCD)的高危因素。方法回顾性分析首都医科大学附属北京安贞医院2005年1月至2014年12月1683例行血运重建术且术前30 d内左心室射血分数(LVEF)≤40%的冠心病心力衰竭患者,根据随访期间是否发生SCD分为SCD组(59例)和无SCD组(1624例),评估住院期间临床基线资料、超声心动图、血管病变及用药情况。结果本研究平均随访(1803±994)d。Cox回归分析发现,三尖瓣反流(HR 2.217,95%CI 1.285~3.827,P=0.004)、左主干+三支病变(HR 3.089,95%CI 1.310~7.283,P=0.010)、尿酸(HR 1.003,95%CI 1.001~1.005,P=0.006)为SCD的独立预测因素。结论尿酸、冠状动脉左主干+三支病变、三尖瓣反流是冠心病心力衰竭患者血运重建术后发生SCD的独立预测因素。

关键词(KeyWords)： 心力衰竭;冠心病;血运重建;高危因素

Abstract:

Keywords:

基金项目(Foundation): 国家重点基础研究发展计划(2015CB554404)

作者(Author): 彭丁,王韶屏,柳景华,白雪莲

参考文献(References)：

• [1]陈伟伟,高润霖,刘力生,等.《中国心血管病报告2016》概要.中国循环杂志,2017,32(6):521-530.
• [2]Podrid PJ,Myerburg RJ.Epidemiology and stratifi cation of risk for sudden cardiac death.Clin cardiol,2005,28(11 Suppl 1):I3-I11.
• [3]Writing Committee M,Yancy CW,Jessup M,et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation,2013,128(16):e240-e327.
• [4]黄德嘉,霍勇,张澍,等.冠心病血运重建后心脏性猝死的预防.中华心律失常学杂志,2017,21(1):9-21.
• [5]Gould PA,Krahn AD,Canadian Heart Rhythm Society Working Group on Device A.Complications associated with implantable cardioverter-defibrillator replacement in response to device advisories.JAMA,2006,295(16):1907-1911.
• [6]Buxton AE,Lee KL,Hafl ey GE,et al.Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease:lessons from the MUSTT study.J Am Coll Eardiol,2007,50(12):1150-1157.
• [7]Myerburg RJ,Mitrani R,Interian A,et al.Interpretation of outcomes of antiarrhythmic clinical trials:design features and population impact.Circulation,1998,97(15):1514-1521.
• [8]Buxton AE,Ellison KE,Lorvidhaya P,et al.Left ventricular ejection fraction for sudden death risk stratifi cation and guiding implantable cardioverter-defibrillators implantation.J Cardiovasc Pharmacol,2010,55(5):450-455.
• [9]Duan X,Ling F.Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure?Med Hypotheses,2008,70(3):578-581.
• [10]Sakai H,Tsutamoto T,Tsutsui T,et al.Serum level of uric acid,partly secreted from the failing heart,is a prognostic marker in patients with congestive heart failure.Circ J,2006,70(8):1006-1011.
• [11]Zhao G,Huang L,Song M,et al.Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality:a meta-analysis of prospective studies.Atherosclerosis,2013,231(1):61-68.
• [12]Neuhold S,Huelsmann M,Pernicka E,et al.Impact of tricuspid regurgitation on survival in patients with chronic heart failure:unexpected fi ndings of a long-term observational study.Eur Heart J,2013,34(11):844-852.
• [13]Kutyifa V,Moss AJ,Klein H,et al.Use of the wearable cardioverter defi brillator in high-risk cardiac patients:data from the Prospective Registry of Patients Using the Wearable Cardioverter Defi brillator(WEARIT-II Registry).Circulation,2015,132(17):1613-1619.
• [14]Zishiri ET,Williams S,Cronin EM,et al.Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defi brillator.Circ Arrhythm Electrophysiol,2013,6(1):117-128.